medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 5

Next >>

Rev Invest Clin 2015; 67 (5)

Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms

Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO

Language: English
References: 56
Page: 280-286
PDF size: 82.29 Kb.


ABSTRACT

The prevalence of clinically evident interstitial lung disease in patients with rheumatoid arthritis is approximately 10%. An additional 33% of undiagnosed patients have interstitial lung abnormalities that can be detected with high-resolution computed tomography. Rheumatoid arthritis-interstitial lung disease patients have three times the risk of death compared to those with rheumatoid arthritis occurring in the absence of interstitial lung disease, and the mortality related to interstitial lung disease is rising. Rheumatoid arthritis-interstitial lung disease is most commonly classified as the usual interstitial pneumonia pattern, overlapping mechanistically and phenotypically with idiopathic pulmonary fibrosis, but can occur in a non-usual interstitial pneumonia pattern, mainly nonspecific interstitial pneumonia. Based on this, we propose two possible pathways to explain the coexistence of rheumatoid arthritis and interstitial lung disease: (i) Rheumatoid arthritis-interstitial lung disease with a non-usual interstitial pneumonia pattern may come about when an immune response against citrullinated peptides taking place in another site (e.g. the joints) subsequently affects the lungs; (ii) Rheumatoid arthritis-interstitial lung disease with a usual interstitial pneumonia pattern may represent a disease process in which idiopathic pulmonary fibrosis-like pathology triggers an immune response against citrullinated proteins that promotes articular disease indicative of rheumatoid arthritis. More studies focused on elucidating the basic mechanisms leading to different sub-phenotypes of rheumatoid arthritis-interstitial lung disease and the overlap with idiopathic pulmonary fibrosis are necessary to improve our understanding of the disease process and to define new therapeutic targets.


REFERENCES

  1. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease associated mortality. Am J Respir Crit Care Med. 2011;183:372-8.

  2. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatology Intern. 2012;32:669-73.

  3. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013;92:92-7.

  4. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Int Med. 2008;168:159-66.

  5. Doyle TJ, Dellaripa PF, Batra K, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014;146:41-50.

  6. BongartzT, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583-91.

  7. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.

  8. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extraarticular manifestations of rheumatoid arthritis. Rheumatology. 2007;46:70-5.

  9. Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66:813-21.

  10. Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015; 74:1772-7.

  11. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoinmmune disease. Nat Rev. 2001;1:147-53.

  12. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019-27.

  13. Sivakumar P, Ntolios P, Jenkins G. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Op Pulm Med. 2012;15:462-9.

  14. Leslie KO. Pathology of interstitial lung disease. Clin Chest Med. 2004;25:657-703.

  15. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, traccional injury to the periphery of the aging lung. Arch Pathol Lab Med. 2012;136:591-600.

  16. Wynn TA. Fibrotic disease and the Th1/Th2 paradigm. Nat Rev Immunol. 2004;4:583-94.

  17. Selman M, Pardo A. Revealing the pathogenic an aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. Am J Resp Crit Care Med. 2013;189:1161-72.

  18. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome- wide association study. Lancet Respir Med. 2013;1:309-17.

  19. Cardenas CL, Kaminski N, Kass DJ. Micromanaging microRNAs: using murine models to study microRNAs in lung fibrosis. Drug Discov Today Dis Models. 2013;10:e145-51.

  20. Liu T, Ullenbruch M, Choi YY. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013;49:260-8.

  21. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756-61.

  22. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti- CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106:1040-7.

  23. Harlowa L, Gochuico BR, Rosas IO, et al. Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses. Clin Immunol. 2014;155:60-70.

  24. Scaly SW, Petersen J, Cheng Law S. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 2013;210:2569-82.

  25. Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26:64-71.

  26. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchusassociated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116:3183-94.

  27. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1227-32.

  28. Evans GW, Kantrowitz E. Socioeconomic status and health: the potential role of environmental risk exposure. Annu Rev Public Health. 2002;23:303-31.

  29. House JS. Understanding social factors and inequalities in health: 20th century progress and 21st century prospects. J Health Soc Behav. 2002;43:125-42.

  30. Mathur C, Stigler MH, Perry CL, et al. Differences in prevalence of tobacco use among Indian urban youth: the role of socioeconomic status. Nicotine Tob Res. 2008;10:109-16.

  31. Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009;11:1-13.

  32. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginin deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67:1488-92.

  33. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322-8.

  34. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

  35. Solomon JJ, Ryu JH, Tazelaar HD. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2013;107:1247-52.

  36. King TE, Costabel U, Cordier JF. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646-64.

  37. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949-61.

  38. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410-15.

  39. Kim EJ, Collard HR, King Jr TE. Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397-405.

  40. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis related lung diseases: CT findings. Radiology. 2004;232:81-91.

  41. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis– associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583-8.

  42. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109-14.

  43. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:67-76.

  44. Doyle TJ, Patel AS, Hatabu H. Detection of rheumatoid arthritisinterstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403-12.

  45. Chen J, Doyle TJ, Liu Y. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67:28-38.

  46. Singh JA, Furst DE , Bharat A. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2012;64: 625-39.

  47. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum. 2014;43: 613-26.

  48. Nakashita T, Ando K, Kaneko N. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615

  49. Koo BS, Hong S, Kim YJ. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an antitumor necrosis factor agent. Korean J Intern Med. 2015;30: 104-9.

  50. Matteson EL, Bongartz T, Ryu JH. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis. 2012;2:53-8.

  51. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-8.

  52. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine and N. Acetyl cytokine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-77.

  53. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin. 2012;8:68-71.

  54. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011;377:1760-9.

  55. King TE, Bradford WZ, Castro Bernadini S, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.

  56. Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.




2020     |     www.medigraphic.com